Ostalo
EFFICACY AND SAFETY OF CERA IN ANEMIA CORRECTION IN PREDIALYSIS PATIENTS - CROATIAN EXPERIENCE
IVAN BUBIĆ
; Zavod za nefrologiju i dijalizu, Klinika za internu medicinu, Klinički bolnički centar Rijeka, Rijeka, Hrvatska
INGRID PRKAČIN
; Klinika za unutarnje bolesti, Klinička bolnica Merkur i Medicinski fakultet Sveučilišta u Zagrebu, Zagreb, Hrvatska
SANJIN RAČKI
; Zavod za nefrologiju i dijalizu, Klinika za internu medicinu, Klinički bolnički centar Rijeka, Rijeka, Hrvatska
Sažetak
Aim: to evaluate efficacy and safety of cera (continuous erythropoietin receptor activator) administration for correcting anemia in the patients with chronic kidney disease (ckd), not on dialysis. methods: We performed observational study on 27 ckd patients in stage 4 or 5 with renal anemia requiring use of erythropoiesis-stimulating agents (esa). all patients received cera (mircera®; roche, basel, switzerland) subcutaneously in dose of 0.6 μg per kg very two weeks during the correction phase of anemia treatment or once monthly during the maintenance treatment. dose of cera was modified according to manufacturer instructions. iron supplementation was administrated orally or intravenously in order to achieve serum ferritin 200-500 μg/L. Patients were followed up to 1 year (from 3-12 months). response riteria for cera were Hb increase
Ključne riječi
anemia; cera; kidney failure; chronic
Hrčak ID:
99538
URI
Datum izdavanja:
3.4.2013.
Posjeta: 1.128 *